-
1
-
-
0035865439
-
Incidence, cost, and outcomes of bleeding and chemotherapy dose modificaton among solid tumor patients with chemotherapy-induced thrombocytopenia
-
Elting LS, Rubenstein EB, Martin CG et al (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137-1146 (Pubitemid 32176291)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.4
, pp. 1137-1146
-
-
Elting, L.S.1
Rubenstein, E.B.2
Martin, C.G.3
Kurtin, D.4
Rodriguez, S.5
Laiho, E.6
Kanesan, K.7
Cantor, S.B.8
Benjamin, R.S.9
-
2
-
-
77953896640
-
Biology and chemistry of thrombopoietic agents
-
Kuter DJ (2010) Biology and chemistry of thrombopoietic agents. Semin Hematol 47:243-248
-
(2010)
Semin Hematol
, vol.47
, pp. 243-248
-
-
Kuter, D.J.1
-
3
-
-
0037111558
-
Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies
-
DOI 10.1182/blood.V100.10.3457
-
Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100:3457-3469 (Pubitemid 35303910)
-
(2002)
Blood
, vol.100
, Issue.10
, pp. 3457-3469
-
-
Kuter, D.J.1
Glenn, B.C.2
-
4
-
-
0035760892
-
Thrombocytopenia caused by the development of antibodies to thrombopoietin
-
Li J, Yang C, Xia Yet al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241- 3248
-
(2001)
Blood
, vol.98
, pp. 3241-3248
-
-
Li, J.1
Yang, C.2
Xia, Y.3
-
5
-
-
0034074551
-
Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
-
Vadhan-Raj S (2000) Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 37:28-34
-
(2000)
Semin Hematol
, vol.37
, pp. 28-34
-
-
Vadhan-Raj, S.1
-
6
-
-
0346881171
-
AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl
-
DOI 10.1016/j.cyto.2003.05.001
-
Broudy VC, Lin NL (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25:52-60 (Pubitemid 38018897)
-
(2004)
Cytokine
, vol.25
, Issue.2
, pp. 52-60
-
-
Broudy, V.C.1
Lin, N.L.2
-
7
-
-
77953896640
-
Biology and chemistry of thrombopoietic agents
-
Kuter DJ (2010) Biology and chemistry of thrombopoietic agents. Semin Hematol 47:243-248
-
(2010)
Semin Hematol
, vol.47
, pp. 243-248
-
-
Kuter, D.J.1
-
8
-
-
84859389743
-
Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics
-
Liebman HA, Pullarkat V (2011) Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematol Am Soc Hematol Educ Program 2011:384-390
-
(2011)
Hematol Am Soc Hematol Educ Program
, vol.2011
, pp. 384-390
-
-
Liebman, H.A.1
Pullarkat, V.2
-
9
-
-
79952708977
-
Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: Results from an open-label dose- and schedule-finding study
-
abstract
-
Fanale M, Stiff P, Noonan K et al (2009) Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study (abstract). EJC Suppl 7:563-563
-
(2009)
EJC Suppl
, vol.7
, pp. 563-563
-
-
Fanale, M.1
Stiff, P.2
Noonan, K.3
-
10
-
-
79952703515
-
Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC)
-
abstract
-
Natale R, Charu V, Schutte Wet al (2009) Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC) (abstract). EJC Suppl 7:574-574
-
(2009)
EJC Suppl
, vol.7
, pp. 574-574
-
-
Natale, R.1
Charu, V.2
Schutte, W.3
-
11
-
-
84897485589
-
Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG531 In chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study
-
abstract
-
Vadhan-Raj S, Hagemeister F, Fayad LE et al (2010) Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG531 In chemotherapy-induced thrombocytopenia (CIT): results of a phase I/II study (abstract). Blood 116:656-657
-
(2010)
Blood
, vol.116
, pp. 656-657
-
-
Vadhan-Raj, S.1
Hagemeister, F.2
Fayad, L.E.3
-
12
-
-
84897533313
-
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study
-
Winer ES, Safran H, Karaszewska B, et al.: Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study. J Clin Oncol (suppl) 30, 2012
-
(2012)
J Clin Oncol
, Issue.SUPPL.
, pp. 30
-
-
Winer, E.S.1
Safran, H.2
Karaszewska, B.3
-
13
-
-
84863454665
-
Leukaemic transformation with romiplostim
-
Gardner K, Mathe S, Sahu S (2012) Leukaemic transformation with romiplostim. Br J Haematol 158:153
-
(2012)
Br J Haematol
, vol.158
, pp. 153
-
-
Gardner, K.1
Mathe, S.2
Sahu, S.3
-
14
-
-
40349103260
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
-
DOI 10.1001/jama.299.8.914
-
Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924 (Pubitemid 351397066)
-
(2008)
JAMA - Journal of the American Medical Association
, vol.299
, Issue.8
, pp. 914-924
-
-
Bennett, C.L.1
Silver, S.M.2
Djulbegovic, B.3
Samaras, A.T.4
Blau, C.A.5
Gleason, K.J.6
Barnato, S.E.7
Elverman, K.M.8
Courtney, D.M.9
McKoy, J.M.10
Edwards, B.J.11
Tigue, C.C.12
Raisch, D.W.13
Yarnold, P.R.14
Dorr, D.A.15
Kuzel, T.M.16
Tallman, M.S.17
Trifilio, S.M.18
West, D.P.19
Lai, S.Y.20
Henke, M.21
more..
-
17
-
-
28344456034
-
Venous thromboembolism: Disease burden, outcomes and risk factors
-
Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost : JTH 3:1611-1617
-
(2005)
J Thromb Haemost: JTH
, vol.3
, pp. 1611-1617
-
-
Heit, J.A.1
-
19
-
-
27744485168
-
How I treat venous thromboembolism in patients with cancer
-
Prandoni P (2005) How I treat venous thromboembolism in patients with cancer. Blood 106:4027-4033
-
(2005)
Blood
, vol.106
, pp. 4027-4033
-
-
Prandoni, P.1
-
20
-
-
19944369810
-
Cancer and venous thromboembolism
-
DOI 10.1016/S1470-2045(05)70207-2, PII S1470204505702072
-
Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401-410 (Pubitemid 40753746)
-
(2005)
Lancet Oncology
, vol.6
, Issue.6
, pp. 401-410
-
-
Prandoni, P.1
Falanga, A.2
Piccioli, A.3
-
21
-
-
70449704426
-
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim
-
Kuter DJ, Mufti GJ, Bain BJ et al (2009) Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 114:3748-3756
-
(2009)
Blood
, vol.114
, pp. 3748-3756
-
-
Kuter, D.J.1
Mufti, G.J.2
Bain, B.J.3
|